Loading...

Home
Stock
GLPG

GLPG News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

GLPG News

Galapagos Enters Binding Agreement with Gilead for Acquisition

Mar 31 2026NASDAQ.COM

Galapagos Enters Binding Agreement with Gilead for Ouro Medicines Acquisition

Mar 31 2026seekingalpha

Galapagos Enters Strategic Collaboration with Gilead

Mar 31 2026Newsfilter

Gilead to Acquire Ouro Medicines for $2.18B, Expanding Inflammation Pipeline

Mar 27 2026Yahoo Finance

Tesla Sees Sales Rebound in Europe and China

Mar 24 2026Fool

Gilead Acquires Ouro to Enhance Portfolio

Mar 24 2026Fool

Gilead Acquires Ouro Medicines for $2.2 Billion, Targeting Future Stock Growth with Key Therapy.

Mar 24 2026Barron's

Galapagos in Advanced Talks for Strategic Collaboration with Gilead

Mar 24 2026Yahoo Finance

GLPG Events

Galapagos Dermatomyositis Treatment Granted FDA Orphan Designation

Galapagos treatment of dermatomyositis was granted FDA orphan designation, according to a post on the agency's website.

Ouro Medicines Reports Q1 Revenue of €6.5M

Reports Q1 revenue EUR 6.5M vs. EUR 75.0M last year. The year-over-year decrease in revenue was primarily driven by the deferred income related to the Gilead drug discovery platform being fully released in revenue at the end of 2025. "Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines' talented team and its portfolio of programs to our Company," said CEO Henry Gosebruch.

GLPG Monitor News

No data

No data

GLPG Earnings Analysis

No Data

No Data

People Also Watch